Nicotinic acetylcholine receptors as targets for antidepressants

被引:0
|
作者
R D Shytle
A A Silver
R J Lukas
M B Newman
D V Sheehan
P R Sanberg
机构
[1] Center for Aging and Brain Repair,Departments of Psychiatry and Behavioral Medicine
[2] University of South Florida College of Medicine,Division of Neurobiology
[3] Center for Infant and Child Development,undefined
[4] University of South Florida College of Medicine,undefined
[5] University of South Florida College of Medicine,undefined
[6] Neurosurgery,undefined
[7] University of South Florida College of Medicine,undefined
[8] Pharmacology,undefined
[9] University of South Florida College of Medicine,undefined
[10] Psychology,undefined
[11] University of South Florida College of Medicine,undefined
[12] Neuroscience Program,undefined
[13] University of South Florida College of Medicine,undefined
[14] Barrow Neurological Institute,undefined
来源
Molecular Psychiatry | 2002年 / 7卷
关键词
nicotinic; mechanism; antidepressant; cholinergic; depression;
D O I
暂无
中图分类号
学科分类号
摘要
While the monoamine deficiency hypothesis of depression is still most commonly used to explain the actions of antidepressant drugs, a growing body of evidence has accumulated that is not adequately explained by the hypothesis. This article draws attention to contributions from another apparently common pharmacological property of antidepressant medications—the inhibition of nicotinic acetylcholine receptors (nAChR). Evidence is presented suggesting the hypercholinergic neurotransmission, which is associated with depressed mood states, may be mediated through excessive neuronal nicotinic receptor activation and that the therapeutic actions of many antidepressants may be, in part, mediated through inhibition of these receptors. In support of this hypothesis, preliminary evidence is presented suggesting that the potent, centrally acting nAChR antagonist, mecamylamine, which is devoid of monoamine reuptake inhibition, may reduce symptoms of depression and mood instability in patients with comorbid depression and bipolar disorder. If this hypothesis is supported by further preclinical and clinical research, nicotinic acetylcholine receptor antagonists may represent a novel class of therapeutic agents for treating mood disorders.
引用
收藏
页码:525 / 535
页数:10
相关论文
共 50 条
  • [41] Palmitoylation of Nicotinic Acetylcholine Receptors
    Alexander, J. K.
    Govind, A. P.
    Drisdel, R. C.
    Blanton, M. P.
    Vallejo, Y.
    Lam, T. T.
    Green, W. N.
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2010, 40 (1-2) : 12 - 20
  • [42] Palmitoylation of Nicotinic Acetylcholine Receptors
    J. K. Alexander
    A. P. Govind
    R. C. Drisdel
    M. P. Blanton
    Y. Vallejo
    T. T. Lam
    W. N. Green
    Journal of Molecular Neuroscience, 2010, 40 : 12 - 20
  • [43] Tricyclic antidepressants inhibit hippocampal α7*and α9α10 nicotinic acetylcholine receptors by different mechanisms
    Arias, Hugo R.
    Vazquez-Gomez, Elizabeth
    Hernandez-Abrego, Andy
    Gallino, Sofia
    Feuerbach, Dominik
    Ortells, Marcelo O.
    Belen Elgoyhen, Ana
    Garcia-Colunga, Jesus
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2018, 100 : 1 - 10
  • [44] Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function
    Fryer, JD
    Lukas, RJ
    JOURNAL OF NEUROCHEMISTRY, 1999, 72 (03) : 1117 - 1124
  • [45] Isolation of a novel conotoxin that targets α7 and α3β2 neuronal nicotinic acetylcholine receptors
    Nicke, AC
    Loughnan, M
    Thomas, L
    Alewood, PF
    Adams, DJ
    Lewis, RJ
    BIOPHYSICAL JOURNAL, 2002, 82 (01) : 560A - 560A
  • [46] Autoimmune Attack of the Neuromuscular Junction in Myasthenia Gravis: Nicotinic Acetylcholine Receptors and Other Targets
    Paz, Mariela L.
    Barrantes, Francisco J.
    ACS CHEMICAL NEUROSCIENCE, 2019, 10 (05): : 2186 - 2194
  • [47] Striatal α6* nicotinic acetylcholine receptors:: Potential targets for Parkinson's disease therapy
    Quik, M
    McIntosh, JM
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 316 (02): : 481 - 489
  • [48] SARS-CoV-2 spike ectodomain targets α7 nicotinic acetylcholine receptors
    O'Brien, Brittany C. V.
    Weber, Lahra
    Hueffer, Karsten
    Weltzin, Maegan M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2023, 299 (05)
  • [49] Nicotinic acetylcholine receptors as therapeutic targets: Emerging frontiers in basic research and clinical science
    Dani, John A.
    Donnelly-Roberts, Diana
    Bertrand, Daniel
    BIOCHEMICAL PHARMACOLOGY, 2015, 97 (04) : 351 - 351
  • [50] Cervical Cancer Correlates with the Differential Expression of Nicotinic Acetylcholine Receptors and Reveals Therapeutic Targets
    Liu, Yiqiao
    Qian, Jiang
    Sun, Zhihua
    Zhangsun, Dongting
    Luo, Sulan
    MARINE DRUGS, 2019, 17 (05)